Search results

ANSTO manufacture and supply a range of radiopharmaceuticals, radiochemicals, kits and accessories for use in research, industry and the health sector.

The nuclear medicine community has welcomed the Australian Government’s decision to provide $30 million in funding to ANSTO for the design of a new nuclear medicine manufacturing facility.

New infrared imaging technique reveals molecular orientation of proteins in silk fibres

ANSTO’s nuclear medicine processing and distribution facility assembles, loads, tests and distributes a range of nuclear medicine products, including Mo-99. The Mo-99 is dispensed into an ANSTO radiopharmaceutical Gentech® Generator where it decays to Tc-99m.

The mining industry is set to benefit from a new Australian capability that uses a nuclear scanning technique to detect the presence of precious metals and strategic minerals in a core sample.

The High Performance Macromolecular Crystallography beamline will enable the study of very small (sub-5 micrometre) or weakly diffracting crystals, providing a state-of-the-art high-throughput facility for researchers. MX3 will be able to study the structures of large proteins and protein complexes for virology, drug design and industrial applications via goniometer mounted crystals, in-tray screening, or via serial crystallography methods.

Neutron imaging or tomography creates a whole series of three-dimensional images of an object that can be reconstructed.

Two approaches use existing low cost and low energy technologies to reuse stockpiled waste from mining operations - capturing carbon dioxide in the form of valuable carbonate minerals.

Detailed molecular structure of silver nanocrystals determined